NASDAQ: RANI — Clinical Stage

Rani imagines a world without needles.

We are developing technology to enable orally administered biologics and drugs.

The RaniPill® is a simple-to-swallow robotic capsule that delivers biologics orally, offering injectable-like bioavailability.

We have the potential to make therapies better — not just more convenient — for the millions of patients with chronic conditions who require biologic drugs.

See how it works → View Pipeline
3
Phase 1 studies completed
20
Molecules assessed in preclinical
400+
Granted & pending patents
Scroll to explore
The Problem

Millions of patients endure painful
injections every year

Rani's platform builds upon trusted medicines and aims to redefine how they are experienced by patients.

1.3M
Injections administered daily in the US alone for biologic therapies
88%
Of patients with an injection regimen of every 2 weeks prefer a daily pill
38%
Of patients who self-administer injections said they frequently skip doses
Millions of patients with chronic conditions require biologic drugs that today can only be injected. These injections are painful, inconvenient, and often affect both patient compliance and quality of life. Patient aversion to injections has promoted a significant interest in the development of solutions to enable the oral delivery of biologics, and we believe the solution is the RaniPill® capsule.
The Breakthrough

How RaniPill® Works

A swallowable auto-injector designed to protect biologic drugs through the stomach and deliver them directly and painlessly through the intestinal wall, mimicking the mechanism of subcutaneous injections to achieve comparable bioavailability and results.

1
Patient swallows the capsule
The RaniPill® capsule moves fully intact through the stomach, where acids typically break down drugs.
2
Capsule reaches the small intestine
The enteric coating protects the payload and dissolves at the appropriate pH, revealing the delivery mechanism inside.
3
Drug is delivered via a dissolveable microneedle
Dissolvable micro-needles deliver the biologic directly into the highly vascularized intestinal wall — a pain free process.
4
Rapid absorption, no trace
The drug is rapidly absorbed into systemic circulation. The self-inflating balloon has been designed to minimize GI discomfort.
Our Pipeline

Advancing across multiple therapeutic areas

Programs in obesity, immunology, endocrinology, and rare disease — with strategic partners.

Program Target / Molecule Indication Phase Partner
RT-114 GLP-1/GLP-2 Obesity Phase 2 ProGen Co., Ltd.
RT-116 Semaglutide Obesity Phase 1 —
RT-105 Adalimumab Biosimilar Psoriatic Arthritis Phase 1 —
RT-111 Ustekinumab Biosimilar Psoriasis Phase 1 —
RT-117 Undisclosed Rare Disease Discovery Chugai Pharmaceutical
RT-114 Phase 2
Target GLP-1/GLP-2
Indication Obesity
Partner ProGen Co., Ltd.
RT-116 Phase 1
Target Semaglutide
Indication Obesity
Partner —
RT-105 Phase 1
Target Adalimumab Biosimilar
Indication Psoriatic Arthritis
Partner —
RT-111 Phase 1
Target Ustekinumab Biosimilar
Indication Psoriasis
Partner —
RT-117 Discovery
Target Undisclosed
Indication Rare Disease
Partner Chugai Pharmaceutical

* Clinical timelines are subject to potential regulatory agency review delays

** RT-114 is the subject of a worldwide collaboration with ProGen Co, Ltd.

*** Ustekinumab and adalimumab biosimilars are supplied by Celltrion, Inc. Celltrion grants Rani a license and drug supply for each drug.

**** RT-117 is the subject of a worldwide collaboration and license with Chugai Pharmaceutical Co., Ltd.

View full pipeline →
Science with Soul

From painful injections
to a simple pill

For millions of patients with chronic conditions, life revolves around injection schedules. Patient aversion to injections has promoted a significant interest in the development of solutions to enable the oral delivery of biologics, and we believe the solution is the RaniPill® capsule.

High reliability
Demonstrated through multiple preclinical and clinical studies.
Safety and tolerability in humans
Proven safety profile with no serious adverse events in clinical trials to date.
Comparable bioavailability
Bioavailability comparable to or better than subcutaneous injections.
Making therapies better, not just more convenient
Ability to maintain or enhance efficacy and safety profiles of established biologics while optimizing dosing and reducing variability.
Biologics Today
Injection
Painful needles, refrigeration, clinic visits, and skipped doses
→
Biologics Tomorrow
RaniPill®
A simple oral capsule — same efficacy, no more needles, better lives
400+
Granted & pending
patent applications
250+
Granted patents
worldwide
102%
Bioavailability
relative to SC
200μL
Liquid drug
capacity

Latest News & Milestones

View all news →
Corporate
May 26, 2026
Rani Therapeutics Holdings, Inc. Announces Pricing of $20.0 Million Registered Direct Offering of Class A Common Stock Priced At-The-Market Under Nasdaq Rules
Events
May 12, 2026
Rani Therapeutics to Participate in the H.C. Wainwright Annual BioConnect Investor Conference
Leadership
April 9, 2026
Rani Therapeutics Appoints Dr. Sara Kenkare-Mitra as Strategic Advisor to Advance Platform and Clinical Strategy

Ready to transform drug delivery?

Whether you're an investor, healthcare professional, or potential partner — let's connect.

Partner with us → Investor Relations